124 related articles for article (PubMed ID: 10644041)
1. Influence of the proto-oncogene c-fos on cisplatin sensitivity.
Moorehead RA; Singh G
Biochem Pharmacol; 2000 Feb; 59(4):337-45. PubMed ID: 10644041
[TBL] [Abstract][Full Text] [Related]
2. Reversal of cisplatin resistance in human ovarian cancer cell lines by a c-jun antisense oligodeoxynucleotide (ISIS 10582): evidence for the role of transcription factor overexpression in determining resistant phenotype.
Pan B; Yao KS; Monia BP; Dean NM; McKay RA; Hamilton TC; O'Dwyer PJ
Biochem Pharmacol; 2002 May; 63(9):1699-707. PubMed ID: 12007573
[TBL] [Abstract][Full Text] [Related]
3. Nucleotide excision repair in the human ovarian carcinoma cell line (2008) and its cisplatin-resistant variant (C13*).
Moorehead RA; Armstrong SG; Rainbow AJ; Singh G
Cancer Chemother Pharmacol; 1996; 38(3):245-53. PubMed ID: 8646799
[TBL] [Abstract][Full Text] [Related]
4. Enhancement of sensitivity of urinary bladder tumor cells to cisplatin by c-myc antisense oligonucleotide.
Mizutani Y; Fukumoto M; Bonavida B; Yoshida O
Cancer; 1994 Nov; 74(9):2546-54. PubMed ID: 7923012
[TBL] [Abstract][Full Text] [Related]
5. Adenoviral delivery of A-FOS, an AP-1 dominant negative, selectively inhibits drug resistance in two human cancer cell lines.
Bonovich M; Olive M; Reed E; O'Connell B; Vinson C
Cancer Gene Ther; 2002 Jan; 9(1):62-70. PubMed ID: 11916245
[TBL] [Abstract][Full Text] [Related]
6. Reversal of cisplatin resistance in vivo by an anti-fos ribozyme.
Funato T; Ishii T; Kanbe M; Scanlon KJ; Sasaki T
In Vivo; 1997; 11(3):217-20. PubMed ID: 9239514
[TBL] [Abstract][Full Text] [Related]
7. Effect of tumor suppressor gene PTEN on the resistance to cisplatin in human ovarian cancer cell lines and related mechanisms.
Wu H; Cao Y; Weng D; Xing H; Song X; Zhou J; Xu G; Lu Y; Wang S; Ma D
Cancer Lett; 2008 Nov; 271(2):260-71. PubMed ID: 18657898
[TBL] [Abstract][Full Text] [Related]
8. Dihydrodiol dehydrogenases regulate the generation of reactive oxygen species and the development of cisplatin resistance in human ovarian carcinoma cells.
Chen J; Adikari M; Pallai R; Parekh HK; Simpkins H
Cancer Chemother Pharmacol; 2008 May; 61(6):979-87. PubMed ID: 17661040
[TBL] [Abstract][Full Text] [Related]
9. Increased expression of dihydrodiol dehydrogenase induces resistance to cisplatin in human ovarian carcinoma cells.
Deng HB; Parekh HK; Chow KC; Simpkins H
J Biol Chem; 2002 Apr; 277(17):15035-43. PubMed ID: 11842089
[TBL] [Abstract][Full Text] [Related]
10. Cyclosporin A suppresses cisplatin-induced c-fos gene expression in ovarian carcinoma cells.
Kashani-Sabet M; Wang W; Scanlon KJ
J Biol Chem; 1990 Jul; 265(19):11285-8. PubMed ID: 2113532
[TBL] [Abstract][Full Text] [Related]
11. SKY1 is involved in cisplatin-induced cell kill in Saccharomyces cerevisiae, and inactivation of its human homologue, SRPK1, induces cisplatin resistance in a human ovarian carcinoma cell line.
Schenk PW; Boersma AW; Brandsma JA; den Dulk H; Burger H; Stoter G; Brouwer J; Nooter K
Cancer Res; 2001 Oct; 61(19):6982-6. PubMed ID: 11585720
[TBL] [Abstract][Full Text] [Related]
12. "Metabolic reprogramming" in ovarian cancer cells resistant to cisplatin.
Montopoli M; Bellanda M; Lonardoni F; Ragazzi E; Dorigo P; Froldi G; Mammi S; Caparrotta L
Curr Cancer Drug Targets; 2011 Feb; 11(2):226-35. PubMed ID: 21158717
[TBL] [Abstract][Full Text] [Related]
13. Human melanoma cell lines selected in vitro displaying various levels of drug resistance against cisplatin, fotemustine, vindesine or etoposide: modulation of proto-oncogene expression.
Kern MA; Helmbach H; Artuc M; Karmann D; Jurgovsky K; Schadendorf D
Anticancer Res; 1997; 17(6D):4359-70. PubMed ID: 9494534
[TBL] [Abstract][Full Text] [Related]
14. Role of the transcription factor Ets-1 in cisplatin resistance.
Wilson LA; Yamamoto H; Singh G
Mol Cancer Ther; 2004 Jul; 3(7):823-32. PubMed ID: 15252143
[TBL] [Abstract][Full Text] [Related]
15. Increase of cisplatin sensitivity by c-myc antisense oligodeoxynucleotides in a human metastatic melanoma inherently resistant to cisplatin.
Leonetti C; Biroccio A; Candiloro A; Citro G; Fornari C; Mottolese M; Del Bufalo D; Zupi G
Clin Cancer Res; 1999 Sep; 5(9):2588-95. PubMed ID: 10499637
[TBL] [Abstract][Full Text] [Related]
16. Synergistic interaction between cisplatin and taxol in human ovarian carcinoma cells in vitro.
Jekunen AP; Christen RD; Shalinsky DR; Howell SB
Br J Cancer; 1994 Feb; 69(2):299-306. PubMed ID: 7905279
[TBL] [Abstract][Full Text] [Related]
17. Expression of the cisplatin resistance phenotype in a human ovarian carcinoma cell line segregates with chromosomes 11 and 16.
Mirakhur B; Parekh HK; Simpkins H
Cancer Res; 1996 May; 56(10):2256-62. PubMed ID: 8625294
[TBL] [Abstract][Full Text] [Related]
18. Ribozyme-mediated cleavage of c-fos mRNA reduces gene expression of DNA synthesis enzymes and metallothionein.
Scanlon KJ; Jiao L; Funato T; Wang W; Tone T; Rossi JJ; Kashani-Sabet M
Proc Natl Acad Sci U S A; 1991 Dec; 88(23):10591-5. PubMed ID: 1660142
[TBL] [Abstract][Full Text] [Related]
19. [Expression and significance of c-fos in resistant cell line TU177/VCR of larynx squamous cell carcinoma].
Li GD; Hu XL; Xing JF; Shi RY; Li X; Li JF; Li TL
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2018 Apr; 53(4):281-285. PubMed ID: 29747253
[No Abstract] [Full Text] [Related]
20. Antisense oligonucleotides targeting c-fos mRNA inhibit rheumatoid synovial fibroblast proliferation.
Morita Y; Kashihara N; Yamamura M; Okamoto H; Harada S; Kawashima M; Makino H
Ann Rheum Dis; 1998 Feb; 57(2):122-4. PubMed ID: 9613344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
